Amgen Shares Drop After AMG 133 Phase II Weight Loss Data Disappoints
2025-06-26
Amgen's AMG 133 showed 16.3-19.9% weight loss (efficacy-based) or 12.3-16.2% treatment policy estimand (TPE) over 52 weeks in Phase II, below expectations. Discontinuation rates reached 29% in high doses due to gastrointestinal side effects. The GIPR antibody-fused GLP-1 therapy is advancing to Phase III for obesity, with additional cardiovascular trials planned.
Despite being a monthly therapy, the results triggered a 5.8% stock drop, valuing Amgen at USD 146.5 billion.
Daily News
Lilly Gains Approval for Once-Daily Oral GLP-1 Agonist for Weight Loss
2026-04-03
Salubris Presents Phase I Data for Hypertension siRNA Therapy
2026-04-03
Alltrna's AP003 Becomes First tRNA Therapy to Enter Human Trials
2026-04-02
XellSmart Raises RMB 500m to Advance Allogeneic iPSC Therapies
2026-04-02
Biogen to Acquire Apellis for USD 5.6b, Gaining First-in-Class C3 Drug
2026-04-01
Latest Report
Global Drug Progress Report during January 2026
Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation